Back to search

Article

Pivmecillinam with Amoxicillin/Clavulanic acid as Step Down Oral Therapy in Febrile Urinary Tract Infections Caused by ESBL-producing Enterobacterales (PACUTI)

2023-02-17

Abstract excerpt

<title>Abstract</title> <p>· <bold>Background</bold>: Oral treatment alternatives for febrile urinary tract infections are limited in the era of increasing antimicrobial resistance. We aim to evaluate if the combination of pivmecillinam and amoxicillin/clavulanic acid is non-inferior to current alternatives for step-down therapy in adult patients with febrile urinary tract infection. · <bold>Methods</bold>: We pl...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
f635250c-9f40-5bf6-b4ca-51fb8e5391d4
DOI
10.21203/rs.3.rs-2598937/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Pivmecillinam with Amoxicillin/Clavulanic acid as Step Down Oral Therapy in Febrile Urinary Tract Infections Caused by ESBL-producing Enterobacterales (PACUTI)DOI 10.21203/rs.3.rs-2598937/v1
Activity of mecillinam against USA urinary tract clinical isolates from 2017 to 2020 including isolates resistant to comparator antibioticsSemantic proximity
Molecular pharmacodynamics of amoxicillin-clavulanic acid against Escherichia coliSemantic proximity
Amoxicillin-Clavulanate Breakpoints AgainstEnterobacterales: Rationale for Revision by the Clinical and Laboratory Standards InstituteSemantic proximity
Effectiveness and Safety of Cefiderocol in Clinical Practice for Treatment of Patients with Gram-Negative Bacterial Infections: US Interim Results of the PROVE StudySemantic proximity
Breaking Down the Breakpoints: Rationale for the 2022 Clinical and Laboratory Standards Institute Revised Piperacillin-Tazobactam Breakpoints Against EnterobacteralesSemantic proximity
Efficacy of ceftolozane/tazobactam against urinary tract and intra-abdominal infections caused by ESBL-producing Escherichia coli and Klebsiella pneumoniae: a pooled analysis of Phase 3 clinical trials.Semantic proximity
PNFLBA-02 A HEAD TO HEAD COMPARATIVE PHASE II TRIAL OF STANDARD URINE CULTURE AND SENSITIVITY VERSUS DNA NEXT GENERATION SEQUENCING TESTING FOR URINARY TRACT INFECTIONSSemantic proximity
Relay oral therapy in febrile urinary tract infections caused by extended spectrum beta-lactamase-producing Enterobacteriaceae in children: A French multicenter study.Semantic proximity
Urine bactericidal activity against Escherichia coli isolates exhibiting different resistance phenotypes/genotypes in an in vitro pharmacodynamic model simulating urine concentrations obtained after oral administration of a 400-milligram single dose of cefditoren-pivoxil.Semantic proximity
Community-onset urinary tract infection in females in the context of COVID-19: a longitudinal population cohort study exploring case presentation, management, and outcomesSemantic proximity
Safety and efficacy of intravenous doripenem for the treatment of complicated urinary tract infections and pyelonephritis.Semantic proximity
Co-resistance between oral antibiotics for pyelonephritis and those for simple urinary tract infections – Applying an Escalation Antibiogram Model to local community dataSemantic proximity
Select a neighboring publication to make it the new centre.